// App-Quantinova.ai

5003 : Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Researchers

Presenter

  • Noel Clarke

Principal Investigators

  • Pawel J. Wiechno

  • Boris Alekseev

  • Nuria Sala

  • Robert Jones

  • Ivo Kocak

  • Vincenzo Emanuele Chiuri

  • Jacek Jassem

  • Aude Flechon

  • Charles Redfern

  • Carsten Dietrich Goessl

  • Joseph Burgents

  • Robert Kozarski

  • Darren R. Hodgson

  • Fred Saad

Medical Centers

  • The Christie and Salford Royal NHS Foundation Trusts, Manchester, United Kingdom

  • Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

  • Moscow Hertzen Cancer Research Institute, Moscow, Russia

  • Catalan Institute of Oncology, Badalona, Spain

  • Velindre Cancer Centre and Cardiff University, Cardiff, United Kingdom

  • Masaryk Memorial Cancer Institute, Brno, Czech Republic

  • Ospedale 'Vito Fazzi', Lecce, Italy

  • Medical University of Gdansk, Gdansk, Poland

  • Centre Leon Berard, Lyon, France

  • Sharp HealthCare, San Diego, CA

  • AstraZeneca, Gaithersburg, MD

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

Locations

  • Czech Republic

  • Canada

  • Italy

  • Poland

  • Spain

  • United Kingdom

  • United States

  • France

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT01972217

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved